Zuclopenthixol

Medical uses

Available forms

Zuclopenthixol is available in three major preparations:

• As zuclopenthixol decanoate (Clopixol Depot, Cisordinol Depot), it is a long-acting intramuscular injection. Its main use is as a long-acting injection given every two or three weeks to people with schizophrenia who have a poor compliance with medication and suffer frequent relapses of illness. There is some evidence it may be more helpful in managing aggressive behaviour.
• As zuclopenthixol acetate (Clopixol-Acuphase, Cisordinol-Acutard), it is a shorter-acting intramuscular injection used in the acute sedation of psychotic inpatients. The effect peaks at 48–72 hours providing 2–3 days of sedation.
• As zuclopenthixol dihydrochloride (Clopixol, Cisordinol), it is a tablet used in the treatment of schizophrenia in those who are compliant with oral medication.

It is also used in the treatment of acute bipolar mania.

Dosing

As a long-acting injection, zuclopenthixol decanoate comes in a 200 mg and 500 mg ampoule. Doses can vary from 50 mg weekly to the maximum licensed dose of 600 mg weekly. In general, the lowest effective dose to prevent relapse is preferred. The interval may be shorter as a patient starts on the medication before extending to 3 weekly intervals subsequently. The dose should be reviewed and reduced if side effects occur, though in the short-term an anticholinergic medication benztropine may be helpful for tremor and stiffness, while diazepam may be helpful for akathisia. 100 mg of zuclopenthixol decanoate is roughly equivalent to 20 mg of flupentixol decanoate or 12.5 mg of fluphenazine decanoate.

In oral form zuclopenthixol is available in 2, 10, 25 and 40 mg tablets, with a dose range of 20–60 mg daily.

Side effects

Chronic administration of zuclopenthixol (30 mg/kg/day for two years) in rats resulted in small, but significant, increases in the incidence of thyroid parafollicular carcinomas and, in females, of mammary adenocarcinomas and of pancreatic islet cell adenomas and carcinomas. An increase in the incidence of mammary adenocarcinomas is a common finding for D2 antagonists which increase prolactin secretion when administered to rats. An increase in the incidence of pancreatic islet cell tumours has been observed for some other D2 antagonists. The physiological differences between rats and humans with regard to prolactin make the clinical significance of these findings unclear.

Withdrawal syndrome: Abrupt cessation of therapy may cause acute withdrawal symptoms (eg, nausea, vomiting, or insomnia). Symptoms usually begin in 1 to 4 days of withdrawal and subside within 1 to 2 weeks.

Other permanent side effects are similar to many other typical antipsychotics, namely extrapyramidal symptoms as a result of dopamine blockade in subcortical areas of the brain. This may result in symptoms similar to those seen in Parkinson's disease and include a restlessness and inability to sit still known as akathisia, a slow tremor and stiffness of the limbs. Zuclopenthixol is thought to be more sedating than the related flupentixol, though possibly less likely to induce extrapyramidal symptoms than other typical depots. As with other dopamine antagonists, zuclopenthixol may sometimes elevate prolactin levels; this may occasionally result in amenorrhoea or galactorrhoea in severe cases. Neuroleptic malignant syndrome is a rare but potentially fatal side effect. Any unexpected deterioration in mental state with confusion and muscle stiffness should be seen by a physician.

Zuclopenthixol decanoate induces a transient dose-dependent sedation. However, if the patient is switched to maintenance treatment with zuclopenthixol decanoate from oral zuclopenthixol or from i.m. zuclopenthixol acetate the sedation will be no problem. Tolerance to the unspecific sedative effect develops rapidly.

;Very common Adverse Effects (≥10% incidence)

• Hypersalivation
• Somnolence
• Akathisia
• Hyperkinesia
• Hypokinesia

;Common (1–10%)

• Tachycardia
• Heart palpitations
• Vertigo
• Accommodation disorder
• Abnormal vision
• Salivary hypersecretion
• Constipation
• Vomiting
• Dyspepsia
• Diarrhoea
• Asthenia
• Fatigue
• Malaise
• Pain (at the injection site)
• Increased appetite
• Weight gain
• Myalgia
• Tremor
• Dystonia
• Hypertonia
• Dizziness
• Headache
• Paraesthesia
• Disturbance in attention
• Amnesia
• Abnormal gait
• Insomnia
• Depression
• Anxiety
• Abnormal dreams
• Agitation
• Decreased libido
• Nasal congestion
• Dyspnoea
• Hyperhidrosis
• Pruritus

;Uncommon (0.1–1%)

• Hyperacusis
• Tinnitus
• Mydriasis
• Abdominal pain
• Nausea
• Flatulence
• Thirst
• Injection site reaction
• Hypothermia
• Pyrexia
• Abnormal liver function tests
• Decreased appetite
• Weight loss
• Muscle rigidity
• Trismus
• Torticollis
• Tardive dyskinesia
• Hyperreflexia
• Dyskinesia
• Parkinsonism
• Syncope
• Ataxia
• Speech disorder
• Hypotonia
• Convulsion
• Migraine
• Apathy
• Nightmares
• Libido increased
• Confused state
• Ejaculation failure
• Erectile dysfunction
• Female orgasmic disorder
• Vulvovaginal
• Dryness
• Rash
• Photosensitivity
• Pigmentation disorder
• Seborrhoea
• Dermatitis
• Purpura
• Hypotension
• Hot flush

;Rare (0.01–0.1%)

• Thrombocytopenia
• Neutropenia
• Leukopenia
• Agranulocytosis
• QT prolongation
• Hyperprolactinaemia
• Hypersensitivity
• Anaphylactic reaction
• Hyperglycaemia
• Glucose tolerance impaired
• Hyperlipidaemia
• Gynaecomastia
• Galactorrhoea
• Amenorrhoea
• Priapism
• Withdrawal symptoms

;Very rare (

• Cholestatic hepatitis
• Jaundice
• Neuroleptic malignant syndrome
• Venous thromboembolism

Pharmacology

Pharmacodynamics

Zuclopenthixol antagonises both dopamine D1 and D2 receptors, α1-adrenoceptors and 5-HT2 receptors with a high affinity, but has no affinity for muscarinic acetylcholine receptors. It weakly antagonises the histamine (H1) receptor but has no α2-adrenoceptor blocking activity .

Evidence from in vitro work and clinical sources (i.e. therapeutic drug monitoring databases) suggests that both CYP2D6 and CYP3A4 play important roles in zuclopenthixol metabolism.

Pharmacokinetics

History

Zuclopenthixol was introduced by Lundbeck in 1978.

References

References

1. "Clopixol (Zuclopenthixol Hydrochloride) Film-coated tablets". The Therapeutics Goods Administration.
2. Anvisa. (2023-03-31). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial". [[Diário Oficial da União]].
3. Sneader, Walter. (2005). "Drug discovery: a history". Wiley.
4. (April 1984). "Pharmacological effects of a specific dopamine D-1 antagonist SCH 23390 in comparison with neuroleptics". Life Sciences.
5. (January 2008). "Substance abuse and schizophrenia: pharmacotherapeutic intervention". Journal of Substance Abuse Treatment.
6. (2009). "Martindale: The complete drug reference". Pharmaceutical Press.
7. (1999). "Zuclopenthixol decanoate for schizophrenia". John Wiley and Sons, Ltd..
8. (2007). "Zuclopenthixol in adults with intellectual disabilities and aggressive behaviours". [[British Journal of Psychiatry]].
9. Lundbeck P/L. (1991). "Clopixol Acuphase 50 mg/mL Injection Clopixol Acuphase 100 mg / 2 mL Injection". Lundbeck P/L.
10. (November 2017). "Zuclopenthixol dihydrochloride for schizophrenia". The Cochrane Database of Systematic Reviews.
11. "Clopixol 2 mg film-coated tablets - Summary of Product Characteristics (SmPC) - (emc)".
12. "Clopixol 2 mg film-coated tablets - Summary of Product Characteristics (SmPC) - (emc)".
13. "UpToDate".
14. "Summary of Product Characteristics".
15. "TGA eBS - Product and Consumer Medicine Information Licence".
16. (2010). "Characterisation of zuclopenthixol metabolism by in vitro and therapeutic drug monitoring studies.". [[Acta Psychiatrica Scandinavica]].
17. William Andrew Publishing. (22 October 2013). "Pharmaceutical Manufacturing Encyclopedia". Elsevier.